Page last updated: 2024-11-05

vincamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Vincamine is a naturally occurring alkaloid extracted from the Madagascar periwinkle (Catharanthus roseus) plant. It is known for its vasodilatory properties, meaning it helps to widen blood vessels, particularly in the brain. This effect is believed to improve cerebral blood flow and oxygen delivery. Vincamine is studied for its potential to treat cognitive decline, particularly in conditions like Alzheimer's disease. Research suggests it may improve memory, attention, and overall cognitive function. However, more research is needed to confirm its efficacy and safety. The synthesis of vincamine involves complex chemical reactions and is typically carried out in a laboratory setting. While there are several synthetic routes, the original process involves the extraction of the alkaloid from the plant material, followed by purification and chemical modifications.'

Vincamine: A major alkaloid of Vinca minor L., Apocynaceae. It has been used therapeutically as a vasodilator and antihypertensive agent, particularly in cerebrovascular disorders. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
VincagenusA plant genus of the family Apocynaceae.[MeSH]ApocynaceaeThe dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH]
Vinca minorspecies[no description available]ApocynaceaeThe dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH]

Cross-References

ID SourceID
PubMed CID15376
CHEMBL ID1165342
CHEBI ID9985
SCHEMBL ID147179
MeSH IDM0022675

Synonyms (103)

Synonym
vincamina
unii-996xvd0jht
vincaminum
996xvd0jht ,
MLS002154249
smr000112509
BRD-K40902647-001-03-7
gtpl349
methyl (15s,17s,19s)-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.0^{2,7}.0^{8,18}.0^{15,19}]nonadeca-2,4,6,8(18)-tetraene-17-carboxylate
PRESTWICK3_000271
BPBIO1_000158
PRESTWICK2_000271
methyl vincaminate
CHEBI:9985 ,
methyl 14beta-hydroxy-14,15-dihydro-3alpha,16alpha-eburnamenine-14alpha-carboxylate
PRESTWICK_495
BCBCMAP01_000080
BSPBIO_000142
devincan
monorin
eburnamenine-14-carboxylic acid, 14,15-dihydro-14-hydroxy-, methyl ester, (3alpha,14beta,16alpha)-
novicet
pervincamine
minorine
vincamin
(+)-vincamine
vincamidol
vincagil
SMP1_000314
1617-90-9
C09251
vincamine
vincamine, 98%
alkaloid obtained from vinca minor
angiopac
arteriovinca
eburnamenine-14-carboxylic acid, 14,15-dihydro-14-hydroxy-, methyl ester, (3alpha,14beta,16.)
14,15-dihydro-14-hydroxyeburnamenine-14-carboxylic acid methyl ester
anasclerol
vincafor
einecs 216-576-3
vincaminum [inn-latin]
vincamine [inn:ban:dcf]
perval
equipur
vincamina [dcit]
hsdb 7150
oxygeron
nsc 91998
PRESTWICK0_000271
PRESTWICK1_000271
SPBIO_002361
methyl (3alpha,14beta,16alpha)-14-hydroxy-14,15-dihydroeburnamenine-14-carboxylate
D08677
vincamine (inn)
cetal retard (tn)
HMS1568H04
CHEMBL1165342
cetal retard
vraap
NCGC00184983-01
HMS2095H04
NCGC00255542-01
dtxsid9040134 ,
dtxcid7020134
tox21_301968
tox21_111342
HMS2268C20
S3891
(3.alpha.,14.beta.,16.alpha.)-14,15-dihydro-14-hydroxyeburnamenine-14-carboxylic acid methyl ester
vincamine [mart.]
vincamine [who-dd]
vincamine [inn]
vincamine [mi]
vincamine [hsdb]
vincamine [ep monograph]
AKOS015896471
CCG-208544
SCHEMBL147179
NCGC00184983-03
tox21_111342_1
KS-5179
CS-4536
Q-100193
HY-B1021
AC-22625
mfcd00078054
eburnamenine-14-carboxylic acid, 14,15-dihydro-14-hydroxy-,methyl ester, (3alpha,14beta,16alpha)-
vincamine, analytical reference material
oxybral
methyl(15s,17s,19s)-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraene-17-carboxylate
methyl (15s,17s,19s)-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.0?,?.0?,??.0??,??]nonadeca-2,4,6,8(18)-tetraene-17-carboxylate
HMS3712H04
DB13374
BCP05837
Q416225
AMY39091
methyl (41s,12s,13as)-13a-ethyl-12-hydroxy-2,3,41,5,6,12,13,13a-octahydro-1h-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate
eburnamenine-14-carboxylic acid, 14,15-dihydro-14-hydroxy-, methylester, (3a,14b,16a)-
methyl (15s,17s,19s)-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraene-17-carboxylate
methyl(41s,12s,13as)-13a-ethyl-12-hydroxy-2,3,41,5,6,12,13,13a-octahydro-1h-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate
(3alpha,14beta,16alpha)-14,15-dihydro-14-hydroxyeburnamenine-14-carboxylic acidmethyl ester
A851579

Research Excerpts

Overview

Vincamine (Vin) is a monoterpenoid indole alkaloid originated from Madagascar periwinkle and was reported as a GPR40 agonist in our previous work. Vincamine is a poorly soluble potent neuroprotector and cerebral vasodilator, used for the treatment for CNS disorders.

ExcerptReferenceRelevance
"Vincamine is a novel phytochemical with promising anti-inflammatory properties."( Vincamine, an active constituent of Vinca rosea ameliorates experimentally induced acute lung injury in Swiss albino mice through modulation of Nrf-2/NF-κB signaling cascade.
Durga Veera Hanuman, D; Gadige, A; Khurana, A; Kumar Banothu, A; Kumar Bharani, K; Mahesh Kumar, J; Mekala, L; Neeradi, D; Patangrao Renushe, A, 2022
)
2.89
"Vincamine (Vin) is a monoterpenoid indole alkaloid originated from Madagascar periwinkle and was reported as a GPR40 agonist in our previous work."( Vincamine as an agonist of G protein-coupled receptor 40 effectively ameliorates pulmonary fibrosis in mice.
Hou, J; Li, H; Qian, M; Shen, X; Wan, H; Wang, J; Zhao, S; Zhao, T; Zhou, Z, 2023
)
3.07
"Vincamine is a naturally occurring indole alkaloid showing antioxidant activity and has been used clinically for the prevention and treatment of cerebrovascular disorders and insufficiencies. "( Vincamine, from an antioxidant and a cerebral vasodilator to its anticancer potential.
DeRose, K; Douglas Kinghorn, A; Gallucci, JC; Li, L; Ren, Y; Yu, J, 2023
)
3.8
"Vincamine is an alkaloid extracted from the Apocynaceae Vinca plant."( Efficacy of Vincamine treatment in a rat model of anterior ischemic optic neuropathy.
Chen, C; Li, L; Liu, J; Su, Y, 2021
)
1.72
"Vincamine is a plant alkaloid used clinically as a peripheral vasodilator that increases cerebral blood flow and oxygen and glucose utilization by neural tissue to combat the effect of aging."( Brain trace element concentration of rats treated with the plant alkaloid, vincamine.
Fayed, AH, 2010
)
1.31
"Vincamine is a poorly soluble potent neuroprotector and cerebral vasodilator, used for the treatment for CNS disorders. "( Rationale of using Vinca minor Linne dry extract phytocomplex as a vincamine's oral bioavailability enhancer.
Cepek, C; Chierotti, MR; Dall'Acqua, S; Gobetto, R; Grabnar, I; Hasa, D; Perissutti, B; Voinovich, D, 2013
)
2.07
"Vincamine is an alkaloid compound derived from the Vinca minor plant. "( Measurement and pharmacokinetics of vincamine in rat blood and brain using microdialysis.
Juan, YP; Tsai, TH, 2005
)
2.05

Effects

Vincamine has an APC of 2.05, a pKa of 6.17, is 64% bound to plasma proteins, and is about 6%bound to erythrocytes. Vincamine was launched since several years for the therapy of cardiovascular disease.

ExcerptReferenceRelevance
"Vincamine has an APC of 2.05, a pKa of 6.17, is 64% bound to plasma proteins, and is about 6% bound to erythrocytes."( Biopharmaceutic and pharmacokinetic aspects of vincamine HCl.
Agrawala, P; Ritschel, WA, 1985
)
1.25
"Pervincamine has been launched since several years for the therapy of cardiovascular disease. "( [Effect of vincamine on blood viscosity].
Ehrly, AM; Landgraf, H, 1982
)
1.28
"Vincamine has no activity in normoxia."( Use of alveolar macrophages in antianoxic drug studies.
Aerts, C; Bianchi, A; Cazin, JC; Cazin, M; Dine, T; Paluszezak, D; Poulain, V, 1988
)
1
"Vincamine has an APC of 2.05, a pKa of 6.17, is 64% bound to plasma proteins, and is about 6% bound to erythrocytes."( Biopharmaceutic and pharmacokinetic aspects of vincamine HCl.
Agrawala, P; Ritschel, WA, 1985
)
1.25

Treatment

Vincamine pretreatment improved kidney functions and decreased kidney function tests as urea, creatinine and kidney injury molecule-1 (KIM-1) Vincamine exhibited antioxidant properties by restoring balance between pro and anti-oxidants of malondialdehyde.

ExcerptReferenceRelevance
"Vincamine pretreatment improved kidney functions and decreased kidney function tests as urea, creatinine and kidney injury molecule-1 (KIM-1), as well as it exhibited antioxidant properties by restoring balance between pro and anti-oxidants of malondialdehyde (MDA), myeloperoxidase (MPO), nuclear factor erythroid 2-related factor 2 (Nrf2) and hemeoxygenase-1 (HO-1)."( Vincamine protects against cisplatin induced nephrotoxicity via activation of Nrf2/HO-1 and hindering TLR4/ IFN-γ/CD44 cells inflammatory cascade.
Abo El Gheit, RE; Badawi, GA; El-Sayed, RM, 2021
)
2.79
"Treatment with vincamine significantly restored these parameters to the normal level."( Antidiabetic, antihyperlipidemic and antioxidant effect of Vincamine, in streptozotocin-induced diabetic rats.
Naik, PR; Nandini, HS, 2019
)
1.1
"Treatment with vincamine (40 mg/kg) effectively ameliorated MTX-induced renal injury via increasing the expression of Nrf2 and HO-1 suppressing oxidative stress, decreasing the expression of inflammatory markers, NF-κB and caspase-3 pathways and enhancing ATP levels."( Involvement of Nrf2/HO-1 antioxidant signaling and NF-κB inflammatory response in the potential protective effects of vincamine against methotrexate-induced nephrotoxicity in rats: cross talk between nephrotoxicity and neurotoxicity.
Awad, AS; Azab, SS; Menze, ET; Shalaby, YM, 2019
)
1.06
"pretreatment with vincamine, trimetazidine and suloctidil (50 mg/kg)."( The effect of ischemia and pharmacological treatment evaluated on synaptosomes and purified mitochondria from rat cerebral cortex.
Benzi, G; Curti, D; Villa, RF, 1981
)
0.59

Pharmacokinetics

The pharmacokinetic parameters were calculated after application of 60 mg vincamine base in comparison to a sustained release formulation (vincamine ratio-pharm 30 mg) on the basis of a GC method.

ExcerptReferenceRelevance
" For all drugs studied, the proposed techniques are specific, reliable and sensitive enough and can be used to perform pharmacokinetic studies in human or in animal after administration of doses in the therapeutic range."( [Quantitative determination of drugs by in situ spectrophotometry of chromatograms for pharmacokinetic studies. I. Sulpiride and other benzamides, vincamine, naftazone (author's transl)].
Bres, J; Bressolle, F; Brun, S; Rechencq, E, 1979
)
0.46
" The pharmacokinetic parameters were calculated after application of 60 mg vincamine base in comparison to a sustained release formulation (vincamine ratio-pharm 30 mg) on the basis of a GC method."( [Relative bioavailability of a vincamine retard formulation. Pharmacokinetic study in normal subjects (author's transl)].
Erking, W; Lücker, PW; Metz, G; Specker, M; Wetzelsberger, K, 1978
)
0.77
" This is confirmed by a pharmacokinetic study and simulation."( Pharmacokinetic aspects of the sublingual administration of vincamine.
Aiache, JM; Delatte, MC; Gomeni, R; Kantelip, JP; Leblanc, PP; Steimer, JL,
)
0.37
" Because the gerbil was used as model in pharmacodynamic studies, the pharmacokinetic drug disposition was determined in this species and compared to parameters reported in the literature for other species."( Biopharmaceutic and pharmacokinetic aspects of vincamine HCl.
Agrawala, P; Ritschel, WA, 1985
)
0.53
" Pharmacokinetic parameters of vincamine were derived using compartmental model."( Measurement and pharmacokinetics of vincamine in rat blood and brain using microdialysis.
Juan, YP; Tsai, TH, 2005
)
0.89

Bioavailability

In the present research a salt of vincamine, a poorly bioavailable indole alkaloid derived from the leaves of Vinca minor L. was studied. Disposition kinetics and oral bioavailability ofvincamine in rabbits were compared after administration of an aqueous solution of the drug and an aQueous colloidal suspension of nanoparticles.

ExcerptReferenceRelevance
" Disposition kinetics and oral bioavailability of vincamine in rabbits were compared after administration of an aqueous solution of the drug and an aqueous colloidal suspension of nanoparticles."( Disposition kinetics and oral bioavailability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles.
Couvreur, P; Devissaguet, JP; Le Verge, R; Maincent, P; Sado, P, 1986
)
0.78
" In oral administration, the overlapping of the fast disposition phase and the absorption phase led to an apparent monocompartmental fit; in both young and aged volunteers, the absorption rate constants as well as the elimination rate constants were calculated."( Pharmacokinetic study of vincamine teprosilate.
Cadórniga, L; Cadórniga, R; Molina, IT; Saiz Vadillo, MC, 1984
)
0.57
" In comparison with an aqueous solution of drug, the absolute bioavailability of vincamine was also increased after an oral administration of nanoparticles."( Preparation and in vivo studies of a new drug delivery system. Nanoparticles of alkylcyanoacrylate.
Couvreur, P; Devissaguet, JP; LeVerge, R; Maincent, P; Sado, PA, 1984
)
0.49
"In a crossover study of six healthy volunteers the pharmacokinetics and the bioavailability of vincamine were studied after administration of two oral forms."( Pharmacokinetic study of two pharmaceutical preparations containing alkaloid vincamine administered orally to human subjects.
Choisy, H; Houin, G; Lamiable, D; Millart, H; Plat, M; Tillement, JP, 1983
)
0.71
" A comparative bioavailability study was then conducted in 16 healthy volunteers for a test versus the reference product by administering a single dose of 60 mg in a crossover design."( In vitro-in vivo correlation and comparative bioavailablity of vincamine in prolonged-release preparations.
el-Menshawi, BS; Emara, LH; Estefan, MY, 2000
)
0.55
"The aims of this research were to prepare highly bioavailable binary cogrounds (vincamine-AcDiSol(®) or PVP-Cl) by means of a mechanochemical process and to study the mediation of each polymer in the induction of physical transformations of the drug."( Mechanochemically induced disordered structures of vincamine: the different mediation of two cross-linked polymers.
Bonifacio, A; Chierotti, MR; Dall'Acqua, S; Gobetto, R; Grabnar, I; Hasa, D; Invernizzi, S; Perissutti, B; Voinovich, D, 2012
)
0.86
" In some cases, the bioavailability of pure compounds is strongly influenced by the co-administration of other constituents, and in some cases, the so called 'phytocomplex' may act as enhancer of absorption of selected phytochemicals."( Rationale of using Vinca minor Linne dry extract phytocomplex as a vincamine's oral bioavailability enhancer.
Cepek, C; Chierotti, MR; Dall'Acqua, S; Gobetto, R; Grabnar, I; Hasa, D; Perissutti, B; Voinovich, D, 2013
)
0.63
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" All of the drugs, with the exception of vinconate, exhibited a monotonic dose-response curve and caused 100% survival at some dose."( Protective effects of vinpocetine and structurally related drugs on the lethal consequences of hypoxia in mice.
King, GA, 1987
)
0.27
" After intravenous administration, total body clearance of vincamine was equal for both dosage forms, but a longer half-life (X 2) and larger distribution volume (X 2) were observed with the suspension of nanoparticles."( Disposition kinetics and oral bioavailability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles.
Couvreur, P; Devissaguet, JP; Le Verge, R; Maincent, P; Sado, P, 1986
)
0.77
"The dose-response relationship of vindeburnol has been investigated by assessing postural activity in a population of elderly patients, using posturography, an objective method for measuring balance."( Dose-response relationship of vindeburnol based on spectral analysis of posturographic recordings.
Foulhoux, P; Le Go, A; Patat, A, 1985
)
0.27
"/ml) at 1 h after dosing and declined biphasically with half-lives of 5 h and 11 h which were similar to half-lives for urinary excretion of 3H."( The metabolic fate of 11-bromo[15-3H]vincamine in man.
Biggs, SR; Chasseaud, LF; Darragh, A; Hawkins, DR; Leaf, FC; Mayo, BC,
)
0.4
" The proposed methods were validated according to ICH guidelines and were successfully applied for the determination of VN and NF in their tablet dosage forms."( Application of π acceptors to the spectrophotometric and spectrofluorimetric determination of vincamine and naftidrofuryl oxalate in their pharmaceutical preparations.
Badr El-Dien, MM; Elbrashy, AM; Ibrahim, FA; Nasr, JJM, 2017
)
0.67
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
vasodilator agentA drug used to cause dilation of the blood vessels.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
vinca alkaloidA group of indole-indoline dimers which are alkaloids obtained from the Vinca genus of plants, together with semi-synthetic and fully synthetic analogues.
alkaloid ester
organic heteropentacyclic compound
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
hemiaminalAny organic amino compound that has an amino group and a hydroxy group attached to the same carbon atom. Hemiaminals are intermediates in the formation of imines by addition of an amine to an aldehyde or ketone; those derived from primary amines are particularly unstable.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATAD5 protein, partialHomo sapiens (human)Potency15.46430.004110.890331.5287AID504466; AID504467
GLI family zinc finger 3Homo sapiens (human)Potency0.72760.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency40.85620.000221.22318,912.5098AID1259247
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency27.17400.001022.650876.6163AID1224839
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency12.58930.01237.983543.2770AID1346984
pregnane X nuclear receptorHomo sapiens (human)Potency18.06750.005428.02631,258.9301AID1346982; AID1346985
cytochrome P450 2D6Homo sapiens (human)Potency10.96400.00108.379861.1304AID1645840
thyroid stimulating hormone receptorHomo sapiens (human)Potency29.34740.001628.015177.1139AID1224843; AID1224895
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency27.184119.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency5.95940.057821.109761.2679AID1159526; AID1159528
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency0.39810.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency33.31790.000323.4451159.6830AID743065; AID743067
Cellular tumor antigen p53Homo sapiens (human)Potency3.21120.002319.595674.0614AID651631
Guanine nucleotide-binding protein GHomo sapiens (human)Potency31.62281.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (129)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (36)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (84)

Assay IDTitleYearJournalArticle
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1546828Antagonist activity at human Gi/o-coupled DRD2L expressed in CHOK1 cells assessed as inhibition in dopamine-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by dopamine addition and measured after 90 or 180 mins by pathhunter be2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1688513Cytoprotective activity in rat INS-1 832/13 cells assessed as inhibition of STZ-induced apoptosis at 20 uM incubated for 24 hrs in presence of wortmannin by MTT assay2020European journal of medicinal chemistry, Feb-15, Volume: 188Design, synthesis and biological evaluation of vincamine derivatives as potential pancreatic β-cells protective agents for the treatment of type 2 diabetes mellitus.
AID1546832Antagonist activity at human Gq-coupled HRH1 expressed in CHOK1 cells assessed as inhibition in histamine-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by histamine addition and measured after 90 or 180 mins by pathhunter bet2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID1546835Antagonist activity at human Gs-coupled PTGIR assessed as inhibition in beraprost-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by beraprost- addition and measured after 90 or 180 mins by pathhunter beta-arrestin assay relati2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1546831Antagonist activity at human Gq-coupled HCRTR2 expressed in CHOK1 cells assessed as inhibition in Orexin A-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by Orexin A addition and measured after 90 or 180 mins by pathhunter bet2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID1546825Antagonist activity at human Gi/o-coupled CNR1 expressed in CHOK1 cells assessed as inhibition in CP55940-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by CP55940 addition and measured after 90 or 180 mins by pathhunter beta-2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID1688505Cytoprotective activity against STZ-induced toxicity in rat INS-1 832/13 cells at 20 uM incubated for 24 hrs by MTT assay2020European journal of medicinal chemistry, Feb-15, Volume: 188Design, synthesis and biological evaluation of vincamine derivatives as potential pancreatic β-cells protective agents for the treatment of type 2 diabetes mellitus.
AID487632Antimelanogenic activity in mouse B16 cells assessed as decrease in intracellular melanin level after 4 days2010Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12
Alpneumines A-H, new anti-melanogenic indole alkaloids from Alstonia pneumatophora.
AID1688510Activation of AKT in STZ-induced rat INS-1 832/13 cells assessed as increase in Akt phosphorylation at 20 uM after 24 hrs by AlphaLISA assay2020European journal of medicinal chemistry, Feb-15, Volume: 188Design, synthesis and biological evaluation of vincamine derivatives as potential pancreatic β-cells protective agents for the treatment of type 2 diabetes mellitus.
AID1546833Antagonist activity at human Gq-coupled NPSR1b expressed in human U2OS cells assessed as inhibition in neuropeptide S-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by neuropeptide S addition and measured after 90 or 180 mins 2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1688514Activation of AKT in STZ-induced rat INS-1 832/13 cells assessed as increase in Akt phosphorylation at 20 uM after 24 hrs in presence of wortmannin by Western blot analysis2020European journal of medicinal chemistry, Feb-15, Volume: 188Design, synthesis and biological evaluation of vincamine derivatives as potential pancreatic β-cells protective agents for the treatment of type 2 diabetes mellitus.
AID1688506Cytoprotective activity against STZ-induced toxicity in rat INS-1 832/13 cells assessed as mass of apoptotic cells at 20 uM by Annexin V-FITC staining based flow cytometric analysis (Rvb = 40.8%)2020European journal of medicinal chemistry, Feb-15, Volume: 188Design, synthesis and biological evaluation of vincamine derivatives as potential pancreatic β-cells protective agents for the treatment of type 2 diabetes mellitus.
AID1546826Antagonist activity at human Gi/o-coupled CNR2 expressed in CHOK1 cells assessed as inhibition in CP55940-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by CP55940 addition and measured after 90 or 180 mins by pathhunter beta-2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID1546829Antagonist activity at human Gi/o-coupled FPR1 expressed in CHOK1 cells assessed as inhibition in WKYMVm-NH2-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by WKYMVm-NH2 addition and measured after 90 or 180 mins by pathhunter2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID1546849Suppression of drug-induced cocaine-seeking behavior in C57BL/6J mouse assessed as reduction in stress-induced reinstatement of morphine-CPP at 60 nmol, icv administered 20 mins prior to testing by forced swim test2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID1546827Antagonist activity at human Gi/o-coupled CXCR4 expressed in mouse C2C12 cells assessed as inhibition in CXCL12-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by CXCL12 addition and measured after 90 or 180 mins by pathhunter 2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID1546823Antagonist activity at human CCR8 expressed in CHOK1 cells assessed as inhibition in CCL1-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by CCL1 addition and measured after 90 or 180 mins by pathhunter beta-arrestin assay rela2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID1546824Antagonist activity at human Gs/Gi/o-coupled CHRM4 expressed in CHOK1 cells assessed as inhibition in acetylcholine-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by acetylcholine addition and measured after 90 or 180 mins by 2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID640615Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
AID221406Compound was tested for the time before the first gasps after ip administration of 2.5 mg/kg in hypoxia test; inactive2001Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23
A novel series of 2,6,7-substituted 2,3-dihydro-1,4-benzodioxin and 2,6,7-substituted 1,4-benzodioxin derivatives as lipid peroxidation inhibitors. Structure-activity relationships for high inhibition of human low-density lipoprotein peroxidation.
AID1546848Suppression of drug-induced cocaine-seeking behavior in C57BL/6J mouse assessed as reduction in morphine-conditioned place preference at 60 nmol, icv administered 20 mins prior to behavioral morphine addition measured twice weekly for 7 weeks2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID487636Antimelanogenic activity in mouse B16 cells assessed as decrease in intracellular melanin level at IC50 after 4 days2010Bioorganic & medicinal chemistry, Jun-15, Volume: 18, Issue:12
Alpneumines A-H, new anti-melanogenic indole alkaloids from Alstonia pneumatophora.
AID1688512Activation of AKT in STZ-induced rat INS-1 832/13 cells assessed as increase in Akt phosphorylation at 20 uM after 24 hrs by Western blot analysis2020European journal of medicinal chemistry, Feb-15, Volume: 188Design, synthesis and biological evaluation of vincamine derivatives as potential pancreatic β-cells protective agents for the treatment of type 2 diabetes mellitus.
AID1688502Cytoprotective activity in rat INS-1 832/13 cells assessed as inhibition of STZ-induced apoptosis incubated for 24 hrs by MTT assay2020European journal of medicinal chemistry, Feb-15, Volume: 188Design, synthesis and biological evaluation of vincamine derivatives as potential pancreatic β-cells protective agents for the treatment of type 2 diabetes mellitus.
AID221113Compound was tested for the time before the first gasps after ip administration of 20 mg/kg in hypoxia test2001Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23
A novel series of 2,6,7-substituted 2,3-dihydro-1,4-benzodioxin and 2,6,7-substituted 1,4-benzodioxin derivatives as lipid peroxidation inhibitors. Structure-activity relationships for high inhibition of human low-density lipoprotein peroxidation.
AID1546830Antagonist activity at human GPR119 assessed as inhibition in oleoylethanolamide-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by oleoylethanolamide addition and measured after 90 or 180 mins by pathhunter beta-arrestin assay2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID1688501Cytoprotective activity in rat INS-1 832/13 cells assessed as inhibition of STZ-induced apoptosis at 20 uM incubated for 24 hrs by MTT assay relative to control2020European journal of medicinal chemistry, Feb-15, Volume: 188Design, synthesis and biological evaluation of vincamine derivatives as potential pancreatic β-cells protective agents for the treatment of type 2 diabetes mellitus.
AID1546834Antagonist activity at human Gq-coupled PRLHR expressed in CHOK1 cells assessed as inhibition in prolactin releasing peptide (1 to 31)-induced beta-arrestin 2 recruitment at 20 uM incubated for 30 mins followed by prolactin releasing peptide (1 to 31) add2020Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10
Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))1997Molecular pharmacology, Jul, Volume: 52, Issue:1
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
AID1345343Human M3 receptor (Acetylcholine receptors (muscarinic))1997Molecular pharmacology, Jul, Volume: 52, Issue:1
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
AID1345465Human M4 receptor (Acetylcholine receptors (muscarinic))1997Molecular pharmacology, Jul, Volume: 52, Issue:1
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
AID1345286Human M1 receptor (Acetylcholine receptors (muscarinic))1997Molecular pharmacology, Jul, Volume: 52, Issue:1
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (292)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990178 (60.96)18.7374
1990's30 (10.27)18.2507
2000's18 (6.16)29.6817
2010's43 (14.73)24.3611
2020's23 (7.88)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 47.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index47.07 (24.57)
Research Supply Index5.84 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index74.62 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (47.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials27 (8.57%)5.53%
Reviews13 (4.13%)6.00%
Case Studies8 (2.54%)4.05%
Observational0 (0.00%)0.25%
Other267 (84.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]